published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsNojomi, 2020 0.49 [0.04; 5.58] Nojomi, 2020 2.04 [0.18; 23.27] 1.00[0.18; 5.59]Nojomi, 2020, Nojomi, 202020%200moderatenot evaluable viral clearance by day 14detailed resultsELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38] 1.84[0.40; 8.38]ELACOI (Lopinavir/ritonavir), 202010%69NAnot evaluable viral clearance by day 7detailed resultsELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89] 1.08[0.41; 2.89]ELACOI (Lopinavir/ritonavir), 202010%69NAnot evaluable severe COVID-19 occurrencedetailed resultsELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27] 0.30[0.07; 1.27]ELACOI (Lopinavir/ritonavir), 202010%69NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-08 04:28 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290